CN117295760A - 与Fc受体结合改变的Fc突变体 - Google Patents

与Fc受体结合改变的Fc突变体 Download PDF

Info

Publication number
CN117295760A
CN117295760A CN202280033488.0A CN202280033488A CN117295760A CN 117295760 A CN117295760 A CN 117295760A CN 202280033488 A CN202280033488 A CN 202280033488A CN 117295760 A CN117295760 A CN 117295760A
Authority
CN
China
Prior art keywords
seq
sequence
index
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033488.0A
Other languages
English (en)
Chinese (zh)
Inventor
付凤根
周帅祥
吴志海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN117295760A publication Critical patent/CN117295760A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280033488.0A 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体 Pending CN117295760A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN2021104953637 2021-05-07
CN202210436873 2022-04-25
CN2022104368731 2022-04-25
PCT/CN2022/091187 WO2022233320A1 (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Publications (1)

Publication Number Publication Date
CN117295760A true CN117295760A (zh) 2023-12-26

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033488.0A Pending CN117295760A (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Country Status (8)

Country Link
US (1) US20240228579A1 (https=)
EP (1) EP4335868A4 (https=)
JP (1) JP2024516320A (https=)
CN (1) CN117295760A (https=)
AU (1) AU2022269145A1 (https=)
CA (1) CA3218187A1 (https=)
TW (1) TWI839729B (https=)
WO (1) WO2022233320A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121712795A (zh) * 2023-08-30 2026-03-20 安斯泰来制药株式会社 Fc区改造体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
RU2639287C2 (ru) * 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2017106684A2 (en) * 2015-12-17 2017-06-22 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Also Published As

Publication number Publication date
JP2024516320A (ja) 2024-04-12
EP4335868A1 (en) 2024-03-13
EP4335868A4 (en) 2025-08-13
US20240228579A1 (en) 2024-07-11
WO2022233320A1 (zh) 2022-11-10
TW202246313A (zh) 2022-12-01
TWI839729B (zh) 2024-04-21
CA3218187A1 (en) 2022-11-10
AU2022269145A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
AU2018344416B2 (en) IgG1 Fc mutants with ablated effector functions
JP6105472B2 (ja) 抗ｈｕＴＮＦＲ１抗体
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
CN111601821B (zh) 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
KR20180030635A (ko) 인간화 또는 키메라 cd3 항체
JP7731359B2 (ja) ヘテロ二量体Ｆｃポリペプチド
KR20240161977A (ko) 항-CD28 x 항-PSMA 항체
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
JP2017529832A (ja) Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体
CN110709417B (zh) 具有突变人IgG4的多肽
JP2026016524A (ja) ハイブリッド抗体
EP4335868A1 (en) Fc mutant with altered binding to fc receptor
US20250340613A1 (en) Bispecific antibody comprising a heterodimer based on mhc proteins
CN117715940A (zh) 抗trem-1抗体
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2025125545A1 (en) Effectorless igg1 fc variants
TW202607021A (zh) 結合ｔｓｌｐ之抗體及使用方法
CN121335921A (zh) 免疫球蛋白Fc区结合蛋白
HK40061359A (en) Antibodies targeting c5ar

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination